BDAZ, I've probably asked this before but I'll ask again.

It strikes me that the RVX BET inhibitor approach with apabetalone (rvx-208) is unique???

You have mentioned that other biotechs are using BET inhibition but they are focused on cancers (perhaps therefore, more in competition with Zenith compounds although if I recall correctly they are not focused on prostate cancers as is zen3694).

So given that CEPT inhibitors have been successful in increasing (non functional?) HDL and have had ZERO impact, as tested so far, on MACE it causes me to think that BP will perhaps begin to focus some attention toward RVX. The statistical data from the CEPT trial "futility analysis" you linked us to were stunning. There was no need to even do stat tests - the test and control group results were indentical for all practicle purposes. There was not even a hint of an e(a)ffect.

rvx-208 achieved a 55% relative reduction on MACE in 6 months with no lasting side effects.

Statins, as I understand it, reduce MACE risk by reducing LDL and we knoow that rvx-208 seems to complement the effects of rosuvastatin(dramatically).

Anyway, I'm rambling. Do you consider apabetalone unique? Thanks.

Also, I sometimes wonder if the multiple effects of apabetalone (from your NYAS notes - Pathways affected include complement cascade, acute phase response, coagulation/fibrin clotting cascade, inflammation and calcification) that this raises doubts about it's effectiveness simply because it is not just one simple clear direct link from production of ApoA-l (functional HDL) to reverse cholesterol transport to reduced MACE (e.g. it cleans out the plaque hence less heart problems). It seems to me that the "pathways affected" (and proven) should be an extremely powerful message and extremely strong support for the power of apabetalone to impact so many indications such as MACE, CKD, DM, PNH, liver fibrosis, muscular dystrophy and even Alzheimers disease. I imagine the scientific commumity specialists are starting to get it and yet science is extremely competitive so many may not want to admit it particularly if they are on a different path and competitors.

I do realize that anytime we throw a chemical into our blood there are many complex reactions created.

However, the apabetalone impacts seem so profound because apabetalone positively impacts so many chronic disease pathways in very positive ways...not destroying like a chemo-therapy...but reconstructing back to healthy states such that cells, protein production can get back to doing what they should do.

This(the positive impacts) of course are a tall order but what we know statistically is that these pathways are positively impacted. That has been proven! And we know the apabetalone reduced MACE by 55% as per post hocs.

Anyway, just thinking out loud again.

GLTA

Toinv